Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study

被引：0
|
作者：
Silberstein, Stephen D. [1 ]
Ashina, Messoud [2 ]
Cohen, Joshua M. [3 ]
Seminerio, Michael J. [3 ]
Yang, Ronghua [3 ]
Ning, Xiaoping [3 ]
Ortega, Mario [3 ]
机构：
[1] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
[2] Univ Copenhagen, Copenhagen, Denmark
[3] Teva Pharmaceut, Frazer, PA USA
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S194
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [21] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine Who Have Failed At least One Prior Preventive Migraine Medication: Results of a 1-Year Study
    Brandes, J.
    Smith, T. R.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 119 - 120
  • [22] Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine who have failed at least one prior preventive migraine medication: results of a 1-year study
    Brandes, Jan L.
    Smith, Timothy R.
    Cohen, Joshua M.
    Yang, Ronghua
    Ning, Xiaoping
    Carr, Karen
    CEPHALALGIA, 2019, 39 : 233 - 233
  • [23] Long-Term Safety of Fremanezumab: Results of a 1-Year Study
    Ning, Xiaoping
    Cohen, Joshua
    Bennett, Nathan
    Yeung, Paul
    Yang, Ronghua
    NEUROLOGY, 2019, 92 (15)
  • [24] Long-Term Safety of Fremanezumab: Results of a 1-Year Study
    Ning, X.
    Cohen, J. M.
    Bennett, N. L.
    Yang, R.
    HEADACHE, 2019, 59 : 47 - 47
  • [25] Long-Term Impact of Fremanezumab on Efficacy in Patients with Chronic Migraine: Interim Results of a One-Year Study
    Cohen, Joshua M.
    McAlister, Peter
    Gandhi, Sanjay
    Yeung, Paul P.
    Fitzgerald, Timothy
    Yang, Ronghua
    Aycardi, Ernesto
    Ma, Mary
    ANNALS OF NEUROLOGY, 2018, 84 : S184 - S184
  • [26] The Long-Term Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine in Patients with Medication Overuse: Results of the COMPEL Study
    Tepper, S. J.
    Wilson, M.
    Orejudos, A.
    Adams, Manack A.
    Blumenfeld, A.
    HEADACHE, 2018, 58 : 93 - 94
  • [27] The long-term efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine in patients with medication overuse: results of the COMPEL study
    Tepper, S.
    Wilson, M. -C.
    Orejudos, A.
    Adams, A. Manack
    Blumenfeld, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 78 - 78
  • [28] Efficacy of Long-Term Fremanezumab Treatment in Patients with Chronic or Episodic Migraine and Prior Inadequate Response to Multiple Migraine Preventive Medication Classes
    Naegel, Steffen
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Barash, Steve
    Ning, Xiaoping
    Carr, Karen
    Kudrow, David
    ANNALS OF NEUROLOGY, 2021, 90 : S132 - S133
  • [29] Long-Term Efficacy of Fremanezumab in Patients With Chronic Migraine With Concomitant Preventive Medication Use
    Yeung, Paul
    Goadsby, Peter
    Jann, Adelene
    Cohen, Joshua
    Yang, Ronghua
    Ning, Xiaoping
    NEUROLOGY, 2019, 92 (15)
  • [30] Long-Term Efficacy of Fremanezumab in Patients with Chronic Migraine with Concomitant Preventive Medication Use
    Goadsby, P. J.
    Jann, A. E.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 117 - 118
12345